Hypoxia-inducible Factor-1alpha Mediates Oral Squamous Cell Carcinoma Invasion Via Upregulation of Alpha5 Integrin and Fibronectin
Overview
Affiliations
With progressive and rapid growth of malignant tumors, cancer cells in an ischemic condition are expected to develop an increased potential for local invasive growth. To address this hypothesis, we first examined the effect of hypoxia on the invasiveness of oral squamous cell carcinoma (OSCC) cells using the Matrigel invasion assay. We then investigated the effect of hypoxia on the protein and mRNA expression of alpha5 integrin and fibronectin, which are major factors involved in tumor cell invasion. We showed that (i) hypoxia increased the invasiveness of OSCC cells, (ii) alpha5 integrin and fibronectin protein and mRNA expression levels were increased in OSCC cells under hypoxic conditions, (iii) hypoxia stimulated autocrine secretion of fibronectin in OSCC cells, (iv) administration of siRNA(HIF-1alpha) caused a significant decrease in alpha5 integrin and fibronectin protein, confirming that HIF-1alpha plays a role in their induction, and (v) siRNA(HIF-1alpha) abrogated hypoxia-induced cell invasion. Collectively, these data suggest that hypoxia promotes OSCC cell invasion that is elicited by HIF-1alpha-dependent alpha5 integrin and fibronectin induction.
PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells.
Yadav A, Wang S, Shin Y, Jang B Int J Mol Sci. 2024; 25(5).
PMID: 38474118 PMC: 10932316. DOI: 10.3390/ijms25052871.
Maruyama S, Yamazaki M, Abe T, Cheng J, Saku T, Tanuma J Biomedicines. 2023; 11(11).
PMID: 38001981 PMC: 10669301. DOI: 10.3390/biomedicines11112981.
The Matrix Reloaded-The Role of the Extracellular Matrix in Cancer.
Raskov H, Gaggar S, Tajik A, Orhan A, Gogenur I Cancers (Basel). 2023; 15(7).
PMID: 37046716 PMC: 10093330. DOI: 10.3390/cancers15072057.
Zhao B, Wu B, Feng N, Zhang X, Zhang X, Wei Y J Hematol Oncol. 2023; 16(1):28.
PMID: 36945046 PMC: 10032017. DOI: 10.1186/s13045-023-01426-4.
Elebyary O, Barbour A, Fine N, Tenenbaum H, Glogauer M Front Oral Health. 2022; 1:584705.
PMID: 35047982 PMC: 8757853. DOI: 10.3389/froh.2020.584705.